***Background.*** Tigecycline has been approved for the treatment of complicated skin and skin structure infections (SSTIs) in the United States (US) since 2005. Since introduction, tigecycline has shown little development of resistance to common pathogens of SSTIs, including methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE) and extended-spectrum β-lactamase (ESBL) --producing *Enterobacteriaceae*. The Tigecycline Evaluation Surveillance Trial (TEST) has been monitoring the activity of tigecycline and comparators against multiple pathogens collected worldwide since 2004. This study reports on the activity of tigecycline against recent clinical isolates from SSTIs in the US.

***Methods.*** A total of 4,229 clinical isolates from SSTI were collected and identified in 124 cumulative sites in the US in 2011-2013. MICs were determined as specified by CLSI at each site using prepared broth microdilution panels and interpreted according to CLSI guidelines. Susceptibility of tigecycline was interpreted using FDA breakpoints.

***Results.*** The ESBL rates for *Escherichia coli* and *Klebsiella pneumoniae* were 6.2% and 11.6%, respectively. 58.2% of *S. aureus* were methicillin-resistant. Summary MIC data (µg/ml) and %S for tigecycline vs select isolates are shown in the table.

  Organism                    N     MIC ~50~   MIC ~90~   %S
  --------------------------- ----- ---------- ---------- ------
  *Acinetobacter baumannii*   271   0.25       2          na
  *Enterobacter* spp.         545   0.5        1          96.2
  *Enterococcus* spp.         377   0.06       0.12       99.7
  ALL VRE Isolates            61    0.06       0.12       100
  *Escherichia coli*          369   0.12       0.25       99.7
  *E. coli*, ESBL             23    0.12       0.5        100
  *Klebsiella pneumoniae*     268   0.5        1          95.5
  *K. pneumoniae*, ESBL       31    0.5        2          93.6
  *Pseudomonas aeruginosa*    426   8          \> 8       na
  *Serratia marcescens*       228   1          2          96.9
  *S. aureus*, MRSA           747   0.12       0.25       100
  *S. aureus*, MSSA           537   0.12       0.12       100

na=No breakpoint available

***Conclusion.*** Tigecycline exhibited excellent *in vitro* activity (93% susceptibility or higher) against major SSTI pathogens from the United States, including resistant phenotypes. MIC~90~ values were 0.12 µg/ml and 0.25 µg/ml for VRE and MRSA, respectively. While MIC~90~ values for ESBL-positive isolates were ≤2 µg/ml, the high rate of ESBL-positive *K. pneumoniae* (11.6%) is cause for concern.
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